Liquid Biopsy in EGFR-Mutated Advanced NSCLC from T790M to MET Amplification: Clinical Implications and Possibilities in the Resistance Setting

被引：0
作者：
Della Gravara, Luigi [1 ]
Battiloro, Ciro [2 ]
Avellino, Aniello [2 ]
Caputo, Francesca [3 ]
D'Aniello, Carmine [3 ]
Rocco, Danilo [2 ]
机构：
[1] Univ Campania Luigi Vanvitelli, Dept Precis Med, I-80138 Naples, Italy
[2] AORN Colli Monaldi, Dept Pulm Oncol, I-80131 Naples, Italy
[3] AORN Colli Monaldi, Dept Med Oncol, I-80131 Naples, Italy
来源：
JOURNAL OF MOLECULAR PATHOLOGY | 2023年 / 4卷 / 02期
关键词：
NSCLC; EGFR; MET; osimertinib; liquid biopsy; NGS; cfDNA; ctDNA; CELL LUNG-CANCER; TREATMENT ALGORITHM; OSIMERTINIB; THERAPY; C797S; 1ST;
D O I：
10.3390/jmp4020009
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
According to the ESMO and ASCO clinical guidelines, the main role of liquid biopsy in EGFR+ advanced NSCLC patients is represented by T790M detection after erlotinib/gefitinib/afatinib progression. However, the general international expert consensus regards osimertinib as the preferred upfront treatment in this setting; therefore, this role has been scaled back in recent years. As of today, liquid biopsy has no ASCO or ESMO recommendation following first-line osimertinib; in the same vein, no targeted therapy has received ASCO or ESMO recommendation following post upfront Osimertinib progression. However, this standard could change in the near future. Therefore, adopting a clinical point of view, this paper aims to provide a comprehensive review on the previous, the current and the possible future role of liquid biopsy in the framework of the diagnostic-therapeutic algorithm of EGFR+ advanced NSCLC.
引用
收藏
页码：81 / 88
页数：8
相关论文
共 59 条
[51]   Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer [J].
Soria, J. -C. ;
Ohe, Y. ;
Vansteenkiste, J. ;
Reungwetwattana, T. ;
Chewaskulyong, B. ;
Lee, K. H. ;
Dechaphunkul, A. ;
Imamura, F. ;
Nogami, N. ;
Kurata, T. ;
Okamoto, I. ;
Zhou, C. ;
Cho, B. C. ;
Cheng, Y. ;
Cho, E. K. ;
Voon, P. J. ;
Planchard, D. ;
Su, W. -C. ;
Gray, J. E. ;
Lee, S. -M. ;
Hodge, R. ;
Marotti, M. ;
Rukazenkov, Y. ;
Ramalingam, S. S. ;
Boyer, Michael ;
Lee, Chee ;
Hughes, Brett ;
O'Byrne, Kenneth ;
Briggs, Peter ;
Milward, Michael ;
John, Thomas ;
Demedts, Ingel ;
Vansteenkiste, Johan ;
Bustin, Frederique ;
Barrios, Carlos Henrique ;
Timcheva, Constanta ;
Butts, Charles ;
Goss, Glenwood ;
Juergens, Rosalyn ;
Leighl, Natasha ;
Cheng, Susanna ;
Burkes, Ronald ;
Zhou, Caicun ;
Zhang, Helong ;
Shu, Yongqian ;
Cheng, Ying ;
Zhou, Qing ;
Li, Wei ;
Feng, Guosheng ;
He, Yong .
NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (02) :113-125
[52]  
Tagrisso plus, AstraZeneca.com
[53]   Alterations of MET Gene Copy Number and Protein Expression in Primary Non-Small-Cell Lung Cancer and Corresponding Nodal Metastases [J].
Tran, Thang N. ;
Selinger, Christina I. ;
Kohonen-Corish, Maija R. J. ;
McCaughan, Brian ;
Kennedy, Catherine ;
O'Toole, Sandra A. ;
Cooper, Wendy A. .
CLINICAL LUNG CANCER, 2016, 17 (01) :30-+
[54]   Lung Adenocarcinoma Harboring EGFR T790M and In Trans C797S Responds to Combination Therapy of First- and Third-Generation EGFR TKIs and Shifts Allelic Configuration at Resistance [J].
Wang, Zhen ;
Yang, Jin-Ji ;
Huang, Jie ;
Ye, Jun-Yi ;
Zhang, Xu-Chao ;
Tu, Hai-Yan ;
Han-Zhang, Han ;
Wu, Yi-Long .
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) :1723-1727
[55]   Phase 1b/2 study of capmatinib plus gefitinib in patients with EGFR-mutated, MET-dysregulated non-small cell lung cancer who received prior therapy: Final overall survival and safety. [J].
Wu, Yi-Long ;
Zhang, Li ;
Kim, Dong-Wan ;
Liu, Xiaoqing ;
Lee, Dae Ho ;
Yang, James Chih-Hsin ;
Ahn, Myung-Ju ;
Vansteenkiste, Johan F. ;
Su, Wu-Chou ;
Felip, Enriqueta ;
Carbini, Mariana ;
Glaser, Sabine ;
Tanriverdi, Oezlem ;
Chassot-Agostinho, Andrea ;
Tan, Daniel Shao-Weng .
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[56]   Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial [J].
Wu, Yi-Long ;
Cheng, Ying ;
Zhou, Jianying ;
Lu, Shun ;
Zhang, Yiping ;
Zhao, Jun ;
Kim, Dong-Wan ;
Soo, Ross Andrew ;
Kim, Sang-We ;
Pan, Hongming ;
Chen, Yuh-Min ;
Chian, Chih-Feng ;
Liu, Xiaoqing ;
Tan, Daniel Shao Weng ;
Bruns, Rolf ;
Straub, Josef ;
Johne, Andreas ;
Scheele, Jurgen ;
Park, Keunchil ;
Yang, James Chih-Hsin .
LANCET RESPIRATORY MEDICINE, 2020, 8 (11) :1132-1143
[57]   Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer [J].
Wu, Yi-Long ;
Zhang, Li ;
Kim, Dong-Wan ;
Liu, Xiaoqing ;
Lee, Dae Ho ;
Yang, James Chih-Hsin ;
Ahn, Myung-Ju ;
Vansteenkiste, Johan F. ;
Su, Wu-Chou ;
Felip, Enriqueta ;
Chia, Vincent ;
Glaser, Sabine ;
Pultar, Philippe ;
Zhao, Sylvia ;
Peng, Bin ;
Akimov, Mikhail ;
Tan, Daniel S. W. .
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (31) :3101-+
[58]   A phase Ib study of the highly selective MET-TKI savolitinib plus gefitinib in patients withEGFR-mutated,MET-amplified advanced non-small-cell lung cancer [J].
Yang, Jin-Ji ;
Fang, Jian ;
Shu, Yong-Qian ;
Chang, Jian-Hua ;
Chen, Gong-Yan ;
He, Jian Xing ;
Li, Wei ;
Liu, Xiao-Qing ;
Yang, Nong ;
Zhou, Caicun ;
Huang, Jian An ;
Frigault, Melanie M. ;
Hartmaier, Ryan ;
Ahmed, Ghada F. ;
Egile, Coumaran ;
Morgan, Shethah ;
Verheijen, Remy B. ;
Mellemgaard, Anders ;
Yang, Liu ;
Wu, Yi-Long .
INVESTIGATIONAL NEW DRUGS, 2021, 39 (02) :477-487
[59]   ORCHARD: A Phase II Platform Study in Patients with Advanced NSCLC Who Have Progressed on First-Line Osimertinib Therapy [J].
Yu, H. ;
Goldberg, S. ;
Le, X. ;
Piotrowska, Z. ;
Smith, P. ;
Mensi, I. ;
Kirova, B. ;
Chmielecki, J. ;
Li-Sucholeicki, X. ;
Szekeres, P. ;
Doughton, G. ;
Patel, G. ;
Jewsbury, P. ;
Riess, J. .
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) :S647-S647
123456